Viatris Inc. will sell its equity stake in Biocon Biologics to Biocon Limited for $815 million, with $400 million in cash and $415 million in newly issued equity shares. The transaction will close in the first quarter of 2026, subject to customary closing conditions. The agreements also accelerate the expiration of biosimilars non-compete restrictions previously placed on Viatris, expiring immediately for ex-U.S. markets and in November 2026 for U.S. markets. The newly issued shares will be listed and traded on the National Stock Exchange of India with a six-month lock-up period.

Read more at Nasdaq: Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln